Abstract
AimsSesamin, the main lignin constituent of sesame, plays a pivotal role in regulating physical state. Some studies have evidenced that the supplementation of sesamin may decrease cardiovascular disease risk. The goal of this systematic review was to summarize evidence of the effects of sesamin supplementation on obesity, blood pressure, and lipid profile in humans by performing a meta-analysis of randomized controlled trials.Data SynthesisFive databases (PubMed, Cochrane Library, EMBASE, Web of Science, and Scopus) were searched electronically from inception to July 2021 to identify randomized controlled trials that assessed the impact of sesamin on obesity, blood pressure, and lipid profile. Weighted mean difference (WMD) and standard deviation (SD) were used to present the major outcomes.ConclusionsSeven trials (n = 212 participants) were included in the overall analysis. Results showed that sesamin supplementation caused a great reduction in TC (WMD: -10.893 mg/dl, 95% CI: −19.745 to −2.041, p = 0.016), LDL-c (WMD: -8.429 mg/dl, 95% CI: −16.086 to −0.771, p = 0.031), and SBP (WMD: −3.662 mmHg, 95% CI: −6.220 to −1.105, p = 0.005), whereas it had no effect on HDL-c, TG, DBP, or weight. Subgroup analysis showed that duration, parallel design, and unhealthy status can affect TC, LDL-c, and SBP evidently. We did not discover a strong link between indicators’ changes and duration of supplementation. Sesamin can be used as an obtainable dietary supplement to improve blood pressure and blood lipids, and further as a health product to prevent cardiovascular diseases.
Highlights
IntroductionThe highest per capita cardiovascular disease (CVD) burden remains in the countries of Eastern Europe and Central Asia [1]
At the global level, the highest per capita cardiovascular disease (CVD) burden remains in the countries of Eastern Europe and Central Asia [1]
Results showed that sesamin supplementation caused a great reduction in total cholesterol (TC) (WMD: -10.893 mg/dl, 95% confidence interval (CI): −19.745 to −2.041, p = 0.016), low-density lipoproteincholesterol (LDL-c) (WMD: -8.429 mg/dl, 95% CI: −16.086 to −0.771, p = 0.031), and SBP (WMD: −3.662 mmHg, 95% CI: −6.220 to −1.105, p = 0.005), whereas it had no effect on high-density lipoprotein-cholesterol (HDL-c), TG, DBP, or weight
Summary
The highest per capita cardiovascular disease (CVD) burden remains in the countries of Eastern Europe and Central Asia [1]. Several published articles have mentioned that potentially modifiable risk factors, such as high blood pressure (BP), raised serum lipids, and obesity may play key roles in promoting the pathogenesis of CVDs [2–4]. Blood profile levels are good indicators of cardiovascular risk and good predictors of coronary disease outcome [5]. Dyslipidemia, defined as elevated levels of triglycerides and cholesterol ( LDL-c) and reduced levels of HDL-c, has been introduced as a strong risk factor for CVD [6, 7]. High blood lipid levels can result in serious damage to systemic blood vessels and organs [8, 9]. Several significant associations have been shown between CVD burden and circulati1ng levels of LDL-c, HDL-c, and triglycerides [10, 11]. Hypertension (systolic blood pressure ≥140 mmHg or diastolic blood pressure ≥90 mmHg) [12] and CVDs are inseparable, too
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
